84.02
price up icon2.13%   1.75
pre-market  プレマーケット:  84.17   0.15   +0.18%
loading
前日終値:
$82.27
開ける:
$82.78
24時間の取引高:
1.23M
Relative Volume:
1.27
時価総額:
$6.72B
収益:
$58.89M
当期純損益:
$-240.88M
株価収益率:
-27.10
EPS:
-3.1
ネットキャッシュフロー:
$-239.96M
1週間 パフォーマンス:
+10.64%
1か月 パフォーマンス:
+14.95%
6か月 パフォーマンス:
+110.73%
1年 パフォーマンス:
+139.03%
1日の値動き範囲:
Value
$81.83
$86.00
1週間の範囲:
Value
$76.52
$86.00
52週間の値動き範囲:
Value
$19.45
$103.00

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
名前
Kymera Therapeutics Inc
Name
セクター
Healthcare (1112)
Name
電話
857-285-5314
Name
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
職員
225
Name
Twitter
Name
次回の収益日
2025-08-01
Name
最新のSEC提出書
Name
KYMR's Discussions on Twitter

Compare KYMR vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
KYMR
Kymera Therapeutics Inc
84.02 6.58B 58.89M -240.88M -239.96M -3.10
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
465.02 117.03B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
783.65 82.35B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
833.54 51.64B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
308.48 42.58B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
346.42 38.87B 4.98B 69.60M 525.67M 0.5198

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-28 再開されました Barclays Overweight
2026-01-06 ダウングレード Wolfe Research Outperform → Peer Perform
2025-11-03 再開されました Guggenheim Buy
2025-10-24 繰り返されました B. Riley Securities Buy
2025-10-21 開始されました Mizuho Outperform
2025-09-18 繰り返されました H.C. Wainwright Buy
2025-09-17 開始されました Barclays Overweight
2025-09-16 開始されました RBC Capital Mkts Outperform
2025-07-30 再開されました B. Riley Securities Buy
2025-07-03 再開されました Morgan Stanley Overweight
2025-06-03 アップグレード B. Riley Securities Neutral → Buy
2025-06-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-06-02 アップグレード BofA Securities Neutral → Buy
2025-05-20 再開されました Stifel Buy
2025-03-13 開始されました Citigroup Buy
2024-12-10 開始されました BTIG Research Buy
2024-12-06 開始されました BMO Capital Markets Market Perform
2024-12-02 アップグレード Wells Fargo Equal Weight → Overweight
2024-11-18 開始されました Stephens Overweight
2024-09-09 再開されました Leerink Partners Outperform
2024-08-26 アップグレード Wolfe Research Peer Perform → Outperform
2024-04-22 開始されました Oppenheimer Outperform
2024-02-15 開始されました Wolfe Research Peer Perform
2024-01-04 アップグレード JP Morgan Neutral → Overweight
2024-01-03 ダウングレード BofA Securities Buy → Neutral
2023-12-19 ダウングレード Wells Fargo Overweight → Equal Weight
2023-06-30 開始されました Truist Buy
2023-05-05 アップグレード Raymond James Mkt Perform → Outperform
2022-12-06 ダウングレード Credit Suisse Outperform → Neutral
2022-11-08 開始されました Raymond James Mkt Perform
2022-08-15 開始されました Jefferies Buy
2022-08-03 開始されました Goldman Buy
2022-07-20 開始されました SVB Leerink Mkt Perform
2022-04-28 開始されました Credit Suisse Outperform
2022-03-10 開始されました JP Morgan Neutral
2022-02-10 開始されました Wells Fargo Overweight
2021-09-30 開始されました B. Riley Securities Neutral
2021-09-30 開始されました Stifel Buy
2021-09-10 ダウングレード BofA Securities Buy → Neutral
2021-05-21 開始されました UBS Buy
2021-04-14 開始されました Berenberg Buy
2020-12-04 開始されました H.C. Wainwright Buy
2020-09-15 開始されました BofA Securities Neutral
2020-09-15 開始されました Cowen Outperform
2020-09-15 開始されました Guggenheim Buy
2020-09-15 開始されました Morgan Stanley Equal-Weight
すべてを表示

Kymera Therapeutics Inc (KYMR) 最新ニュース

pulisher
Feb 11, 2026

Kymera at Guggenheim Biotech Summit: Exploring Oral Drug Potential By Investing.com - Investing.com Canada

Feb 11, 2026
pulisher
Feb 11, 2026

Kymera Therapeutics, Inc. $KYMR Shares Acquired by Candriam S.C.A. - MarketBeat

Feb 11, 2026
pulisher
Feb 07, 2026

Certain Warrants of Kymera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2026. - marketscreener.com

Feb 07, 2026
pulisher
Feb 07, 2026

Certain Restricted Stock Units of Kymera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2026. - marketscreener.com

Feb 07, 2026
pulisher
Feb 07, 2026

Certain Common Stock of Kymera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2026. - marketscreener.com

Feb 07, 2026
pulisher
Feb 07, 2026

CEO Moves: Will FATN outperform small cap indexesJuly 2025 Snapshot & Long-Term Safe Investment Ideas - baoquankhu1.vn

Feb 07, 2026
pulisher
Feb 05, 2026

Kymera Therapeutics (KYMR) Is Up 7.0% After Advancing Dual Phase 2b Trials for KT-621 - Sahm

Feb 05, 2026
pulisher
Feb 05, 2026

Smart Money: What are Kymera Therapeutics Incs earnings expectationsOptions Play & Daily Momentum Trading Reports - baoquankhu1.vn

Feb 05, 2026
pulisher
Feb 04, 2026

KYMR initiates dosing in mid-stage asthma study of lead candidate - MSN

Feb 04, 2026
pulisher
Feb 04, 2026

Kymera Therapeutics to Participate in Upcoming February Investor Conferences - Investing News Network

Feb 04, 2026
pulisher
Feb 03, 2026

Kymera Therapeutics (KYMR): A Biotech Stock with 54% Potential Upside Amid Innovative Protein Degradation Focus - DirectorsTalk Interviews

Feb 03, 2026
pulisher
Feb 03, 2026

(KYMR) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Feb 03, 2026
pulisher
Feb 03, 2026

Deep Dive Into Kymera Therapeutics Stock: Analyst Perspectives (21 Ratings) - Benzinga

Feb 03, 2026
pulisher
Feb 03, 2026

Kymera Therapeutics (NASDAQ:KYMR) Receives Buy Rating from BTIG Research - MarketBeat

Feb 03, 2026
pulisher
Feb 03, 2026

BTIG Reiterates Buy Rating for Kymera Therapeutics (KYMR) with $ - GuruFocus

Feb 03, 2026
pulisher
Feb 02, 2026

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Feb 02, 2026
pulisher
Feb 01, 2026

Knights of Columbus Asset Advisors LLC Acquires New Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Feb 01, 2026
pulisher
Jan 31, 2026

Federated Hermes Inc. Makes New Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Jan 31, 2026
pulisher
Jan 31, 2026

Kymera Starts Phase 2b Asthma Trial Testing Oral STAT6 Degrader KT-621 - Yahoo Finance

Jan 31, 2026
pulisher
Jan 30, 2026

KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate - Yahoo Finance

Jan 30, 2026
pulisher
Jan 29, 2026

Kymera begins dosing in phase 2b asthma trial for oral STAT6 degrader By Investing.com - Investing.com South Africa

Jan 29, 2026
pulisher
Jan 29, 2026

Kymera begins dosing in phase 2b asthma trial for oral STAT6 degrader - Investing.com India

Jan 29, 2026
pulisher
Jan 29, 2026

Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader - Investing News Network

Jan 29, 2026
pulisher
Jan 29, 2026

Kymera Therapeutics Announces First Patient Dosed In Breadth Phase 2B Asthma Clinical Trial Of KT-621, A First-In-Class, Oral Stat6 Degrader - TradingView

Jan 29, 2026
pulisher
Jan 28, 2026

Analyst Barclays Raises Price Target for Kymera Therapeutics (KY - GuruFocus

Jan 28, 2026
pulisher
Jan 28, 2026

Aug Movers: Can Kymera Therapeutics Inc benefit from deglobalization2025 Fundamental Recap & Weekly Breakout Watchlists - baoquankhu1.vn

Jan 28, 2026
pulisher
Jan 28, 2026

Kymera Therapeutics (KYMR) Stock Analysis: Exploring A 64% Upside Potential - DirectorsTalk Interviews

Jan 28, 2026
pulisher
Jan 28, 2026

What is the earnings history of Kymera Therapeutics Inc.2025 Trading Recap & Reliable Price Breakout Signals - mfd.ru

Jan 28, 2026
pulisher
Jan 23, 2026

Responsive Playbooks and the KYMR Inflection - Stock Traders Daily

Jan 23, 2026
pulisher
Jan 22, 2026

Aug Volume: What is the long term forecast for Kymera Therapeutics Inc stockWall Street Watch & Fast Exit and Entry Strategy Plans - baoquankhu1.vn

Jan 22, 2026
pulisher
Jan 22, 2026

Assessing Kymera Therapeutics (KYMR) Valuation After Milestone Updates For KT-621 And Partnered IRAK4 Programs - Sahm

Jan 22, 2026
pulisher
Jan 21, 2026

Is BRID stock overvalued or fairly pricedJuly 2025 Sentiment & Community Trade Idea Sharing Platform - baoquankhu1.vn

Jan 21, 2026
pulisher
Jan 20, 2026

Kymera Therapeutics director Esposito sells $373k in shares By Investing.com - Investing.com Nigeria

Jan 20, 2026
pulisher
Jan 20, 2026

Kymera Therapeutics director Esposito sells $373k in shares - Investing.com

Jan 20, 2026
pulisher
Jan 19, 2026

This drugmaker's stock is soaring over 40% Monday - MSN

Jan 19, 2026
pulisher
Jan 19, 2026

Signal Recap: Does Loop Industries Inc outperform in volatile marketsMarket Activity Report & Safe Swing Trade Setups - baoquankhu1.vn

Jan 19, 2026
pulisher
Jan 18, 2026

Exit Recap: Can Kymera Therapeutics Inc benefit from deglobalizationJuly 2025 Chart Watch & Real-Time Stock Entry Alerts - baoquankhu1.vn

Jan 18, 2026
pulisher
Jan 18, 2026

Portfolio Update: What is Kymera Therapeutics Incs 5 year growth outlookWeekly Earnings Recap & Consistent Profit Focused Trading Strategies - baoquankhu1.vn

Jan 18, 2026
pulisher
Jan 17, 2026

Kymera Therapeutics, Inc. (KYMR) up 28% in 3M, analysts see further upside - MSN

Jan 17, 2026
pulisher
Jan 15, 2026

Is Kymera Therapeutics (KYMR) Turning Its Immunology Pipeline Into a Durable Platform Advantage? - Sahm

Jan 15, 2026
pulisher
Jan 15, 2026

Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (25 Ratings) - Benzinga

Jan 15, 2026
pulisher
Jan 15, 2026

Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside - Finviz

Jan 15, 2026
pulisher
Jan 15, 2026

Muted and missing M&As: JPM deals absent in 2026 - BioWorld MedTech

Jan 15, 2026
pulisher
Jan 15, 2026

BTIG Research Reaffirms Buy Rating for Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat

Jan 15, 2026
pulisher
Jan 14, 2026

Kymera Therapeutics prices $602M public offering at $86.00 a share - MSN

Jan 14, 2026
pulisher
Jan 13, 2026

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Portfolio of Oral Immunology Programs - marketscreener.com

Jan 13, 2026
pulisher
Jan 13, 2026

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs - Investing News Network

Jan 13, 2026
pulisher
Jan 13, 2026

Kymera Therapeutics Sets 2026 Clinical Strategy and Milestones - TipRanks

Jan 13, 2026
pulisher
Jan 13, 2026

Kymera Therapeutics (KYMR): Investor Outlook On Biotech's 59.75% Upside Potential - DirectorsTalk Interviews

Jan 13, 2026
pulisher
Jan 13, 2026

Kymera Therapeutics Outlines 2026 Milestones, Advances Clinical Trials for Immunology Candidates - Quiver Quantitative

Jan 13, 2026

Kymera Therapeutics Inc (KYMR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$44.80
price up icon 1.24%
$26.75
price down icon 0.19%
$100.75
price up icon 1.93%
$105.76
price down icon 3.31%
$146.17
price down icon 1.52%
biotechnology ONC
$346.42
price down icon 1.38%
大文字化:     |  ボリューム (24 時間):